[The study of the efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia]. / Issledovanie éffektivnosti i bezopasnosti primeneniia Meksidola i Meksidola Forte 250 u bol'nykh s khronicheskoi ishemiei mozga.

AIM: To study the efficacy and safety of Mexidol used intravenously (500 mg 1 time per day) for 14 days, followed by the oral administration of Mexidol Forte 250 in a dose of 250 mg 3 times a day for 60 days, in patients with chronic cerebral ischemia (CCI). MATERIAL AND METHODS: The study included 56 patients with CCI due to a combination of hypertension and atherosclerosis. The results of physical examinations (control of blood pressure, heart rate etc.), dynamics of complaints, scores on CGI, MoCa, MFI-20, HRSD, HARS and the Tinetti test were evaluated. RESULTS AND CONCLUSION: The high level of efficacy and safety of intravenous injections of Mexidol followed by the oral administration of Mexidol Forte 250 are demonstrated. This scheme of therapy contributes to a significant decrease in the objective and subjective symptoms of CCI, leads to improvements in the emotional, cognitive and motor spheres.

[The use of neuroleptics in the treatment of hyperkinetic behavioral disorders in children]. / Primenenie neiroleptikov v terapii giperkineticheskogo rasstroistva povedeniia u detei.

AIM: To compare the efficacy of thioridazine and tiapride in treatment of hyperkinetic behavioral disorders (HBD) in children. MATERIAL AND METHODS: The study included 60 children, детей, 42 boys and 18 girls, mean age 8.0±2.0 years. Patients were divided into two equal groups. The duration of the study was 30 days. The Achenbach System of Empirically Based Assessment (ASEBA) was used. Safety was assessed by sedation scores and serum prolactin levels. RESULTS AND CONCLUSION: A positive effect of both drugs was shown. The levels of aggression and delinquency decreased significantly, while a decrease in attention levels was less pronounced. Both drugs were similar by efficacy, but tiapride had better safety profile.

[Clinical manifestations of antiphospholipid syndrome associated with lesions of the central nervous system].

Antiphospholipid syndrome (APS) is one of the important but poorly known conditions. Its symptoms are ofparticular interest for neurologists since thrombi are most often localized in the cerebral blood vessels which leads to ischemic cerebrovascular accidents (AICS). APS can also manifest itself in the following symptoms: epileptic attacks, dementia, headache, chorea, peripheral neuropathy, myelo- and encephalopathy phenomenologically similar to multiple sclerosis. This article presents a clinical case of secondary APS with the neurological manifestations in a 25-year-old female patient.